&lt;p&gt;Integrating tacrolimus into eutectic oil-based microemulsion for atopic dermatitis: simultaneously enhancing percutaneous delivery and treatment efficacy with relieving side effects&lt;/p&gt;

Wang, Yixuan; Cao, Sisi; Yu, Kaiyue; Yang, Fengdie; Yu, Xiuming; Zhai, Yuanhao; Wu, Chuanbin; Xu, Yang

doi:10.2147/ijn.s212260

Cited by 20 publications

(10 citation statements)

References 49 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8) . Our findings were following those of other research using HaCaT cell lines to assess the safety of several recently produced formulations 30,31) . We found that petrolatum-LC formulations had no genotoxic reaction against HaCaT cells even when used at 1 mg/mL (Figs.…”

Section: Discussionsupporting

confidence: 87%

Development and Evaluation of Biocompatible Topical Petrolatum-liquid Crystal Formulations with Enhanced Skin Permeation Properties

Al-Zuhairy¹,

Kadhum²,

Alhijjaj

et al. 2022

J. Oleo Sci.

View full text Add to dashboard Cite

IntroductionThe first line of defence is the skin, preventing foreign things from entering the human body system and preventing water loss from the body via evaporation 1,2) . The stratum corneum is a complex outermost layer of the skin that acts as the initial physical barrier to any external elements, including medicines, entering the body, which also makes an obstacle in the drug penetration into the body 2) . However, owing to its simple and convenient accessibility, the skin remains an appealing route of drug administration,

show abstract

Section: Discussionsupporting

confidence: 87%

Development and Evaluation of Biocompatible Topical Petrolatum-liquid Crystal Formulations with Enhanced Skin Permeation Properties

Al-Zuhairy¹,

Kadhum²,

Alhijjaj

et al. 2022

J. Oleo Sci.

View full text Add to dashboard Cite

show abstract

“…Bacterial infections are very common, particularly due to Staphylococcus and Streptococcus strains which contribute to erythema aggravation [28][29][30]. Currently, pharmacological treatments involve the use of corticosteroids and antihistamines, while the most serious cases require the use of immunomodulating agents [31,32]. Thus, the research of new molecules that can represent a helpful therapy for conventional drugs is certainly a great resource that should not be underestimated.…”

Section: Discussionmentioning

confidence: 99%

Effect of a Product Containing Xyloglucan and Pea Protein on a Murine Model of Atopic Dermatitis

Campolo

Casili

Paterniti

et al. 2020

IJMS

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a chronic inflammatory disease of the skin, characterized by dryness and more or less severe itching. The etiology of AD is complex and has not been fully clarified, involving genetic susceptibility, immunological abnormalities, epidermal barrier dysfunction, and environmental factors. Xyloglucan (XG) and pea protein (PP) are two compounds of natural origin characterized by the ability to create a physical barrier that protects mucosae membranes, reducing inflammation. The aim of the present study was to evaluate the potential beneficial effects of XG + PP in both a mouse model of AD and Staphylococcus aureus (S. aureus) infection- associated AD. Mice were topically treated with 200 μL of 0.5% oxazolone on the dorsal skin three times a week for AD induction. Mice received XG and PP by topical administration 1 h before oxazolone treatment. In S. aureus infection-associated AD, to induce a superficial superinfection of the skin, mice were also treated with 5 μL of 108 of a culture of S. aureus for 2 weeks; mice superinfected received XG and PP by topical administration 1 h before oxazolone + S. aureus. Four weeks later, the skin was removed for histological and biochemical analysis. Our results demonstrated the protective barrier effects of XG and PP characterized by a reduction in histological tissue changes, mastocyte degranulation, and tight junction permeability in the skin following oxazolone treatment. Moreover, XG + PP was able to preserve filaggrin expression, a hallmark of AD. Our data also support the effectiveness of XG + PP to reduce the damage by superinfection post AD induced by S. aureus. In conclusion, a future product containing XG and PP could be considered as a potentially interesting approach for the treatment of AD.

show abstract

“…The spleen index is an important indicator for reflecting the abnormal immune activation in the AD mouse model [27]. As shown as Figure 3A, BIS dose dependently reduced the spleen index, which was calculated by weight of spleen/weight of body × 100%.…”

Section: Bis Relieved Abnormal Immune Responsementioning

confidence: 99%

(-)-α-Bisabolol Alleviates Atopic Dermatitis by Inhibiting MAPK and NF-κB Signaling in Mast Cell

Sun

et al. 2022

Molecules

View full text Add to dashboard Cite

(-)-α-Bisabolol (BIS) is a sesquiterpene alcohol derived mostly from Matricaria recutita L., which is a traditional herb and exhibits multiple biologic activities. BIS has been reported for treatment of skin disorders, but the effect of BIS on anti-atopic dermatitis (AD) remains unclear. Therefore, we investigated the effects of BIS on 2,4-dinitrochlorobenzene (DNCB)-induced AD in BALB/c mice and the underlying mechanism in Bone Marrow-Derived Mast Cells (BMMCs). Topical BIS treatment reduced AD-like symptoms and the release of interleukin (IL)-4 without immunoglobulin (Ig)-E production in DNCB-induced BALB/c mice. Histopathological examination revealed that BIS reduced epidermal thickness and inhibited mast cells in the AD-like lesions skin. Oral administration of BIS effectively and dose-dependently suppressed mast-cell-mediated passive cutaneous anaphylaxis. In IgE-mediated BMMCs, the levels of β-hexosaminidase (β-hex), histamine, and tumor necrosis factor (TNF)-α were reduced by blocking the activation of nuclear factor-қB (NF-қB) and c-Jun N-terminal kinase (JNK) without P38 mitogen activated protein (P38) and extracellular regulated protein kinases (Erk1/2). Taken together, our experimental results indicated BIS suppresses AD by inhibiting the activation of JNK and NF-κB in mast cells. BIS may be a promising therapeutic agent for atopic dermatitis and other mast-cell-related diseases.

show abstract

<p>Integrating tacrolimus into eutectic oil-based microemulsion for atopic dermatitis: simultaneously enhancing percutaneous delivery and treatment efficacy with relieving side effects</p>

Cited by 20 publications

References 49 publications

Development and Evaluation of Biocompatible Topical Petrolatum-liquid Crystal Formulations with Enhanced Skin Permeation Properties

Development and Evaluation of Biocompatible Topical Petrolatum-liquid Crystal Formulations with Enhanced Skin Permeation Properties

Effect of a Product Containing Xyloglucan and Pea Protein on a Murine Model of Atopic Dermatitis

(-)-α-Bisabolol Alleviates Atopic Dermatitis by Inhibiting MAPK and NF-κB Signaling in Mast Cell

Contact Info

Product

Resources

About